Covered recipient · General Payments record
LAWRENCE GOLDSTICK
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$86,372.78
268 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,576.50 | 20 |
| Consulting Fee | $13,008.50 | 3 |
| Travel and Lodging | $6,408.62 | 13 |
| Food and Beverage | $6,228.22 | 229 |
| Education | $150.94 | 3 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $30,949.96 | 46 |
| Biogen, Inc. | $19,520.91 | 33 |
| E.R. Squibb & Sons, L.L.C. | $15,886.63 | 7 |
| Eli Lilly and Company | $8,750.00 | 1 |
| GENZYME CORPORATION | $5,973.52 | 16 |
| Lilly USA, LLC | $2,230.09 | 23 |
| Horizon Therapeutics plc | $316.30 | 11 |
| Celgene Corporation | $272.05 | 7 |
| SK Life Science, Inc. | $261.07 | 14 |
| EISAI INC. | $237.67 | 13 |
| Genentech USA, Inc. | $200.03 | 10 |
| Novartis Pharmaceuticals Corporation | $191.12 | 16 |
| ABBVIE INC. | $189.65 | 8 |
| Alexion Pharmaceuticals, Inc. | $153.66 | 10 |
| Neurocrine Biosciences, Inc. | $153.01 | 9 |
| UCB, Inc. | $150.99 | 8 |
| Mallinckrodt Hospital Products Inc. | $148.52 | 2 |
| Biohaven Pharmaceutical Holding Company Ltd. | $137.57 | 7 |
| Janssen Pharmaceuticals, Inc | $132.82 | 3 |
| Teva Pharmaceuticals USA, Inc. | $125.96 | 9 |
| Genentech, Inc. | $118.50 | 1 |
| ARGENX US, INC. | $59.42 | 2 |
| Neurelis, Inc. | $48.55 | 3 |
| Amgen Inc. | $47.98 | 3 |
| Avanir Pharmaceuticals, Inc. | $44.98 | 2 |
| Corium, LLC | $24.67 | 1 |
| Avion Pharmaceuticals | $19.18 | 1 |
| Supernus Pharmaceuticals, Inc. | $16.16 | 1 |
| Banner Life Sciences, LLC | $11.81 | 1 |
Page 5 of 6; records 201–250 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAWRENCE GOLDSTICK
NPI 1508969445 · CMS profile ID 67920
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
DAYTON, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 6; records 201–250 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508969445?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508969445?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508969445?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LAWRENCE GOLDSTICK, NPI 1508969445, CMS profile ID 67920, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 268 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508969445?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
268 matching records · $86,372.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 268.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.72 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891051667 | CMS |
| EISAI INC. | $21.97 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908056855 | CMS |
| EMD Serono, Inc. | $16.79 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941504817 | CMS |
| EMD Serono, Inc. | $65.00 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941504893 | CMS |
| Genentech USA, Inc. | $22.61 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950784449 | CMS |
| Neurocrine Biosciences, Inc. | $13.13 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963271425 | CMS |
| Novartis Pharmaceuticals Corporation | $5.88 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893707023 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.29 | 04/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954684511 | CMS |
| Novartis Pharmaceuticals Corporation | $16.09 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893707029 | CMS |
| Celgene Corporation | $16.17 | 03/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932728139 | CMS |
| Horizon Therapeutics plc | $23.88 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937625975 | CMS |
| Celgene Corporation | $6.94 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932728129 | CMS |
| EMD Serono, Inc. | $18.50 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941502025 | CMS |
| EMD Serono, Inc. | $63.32 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941502047 | CMS |
| EMD Serono, Inc. | $642.19 | 03/24/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941502049 | CMS |
| Lilly USA, LLC | $12.85 | 03/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918123721 | CMS |
| EMD Serono, Inc. | $98.73 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941501573 | CMS |
| Supernus Pharmaceuticals, Inc. | $16.16 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 952963459 | CMS |
| EMD Serono, Inc. | $16.98 | 03/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941501553 | CMS |
| EISAI INC. | $15.10 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908056849 | CMS |
| Biogen, Inc. | $16.86 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923402075 | CMS |
| EMD Serono, Inc. | $29.41 | 03/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941499711 | CMS |
| EMD Serono, Inc. | $253.49 | 03/12/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941499871 | CMS |
| EMD Serono, Inc. | $92.11 | 03/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941499903 | CMS |
| EMD Serono, Inc. | $73.53 | 03/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941499999 | CMS |
| EMD Serono, Inc. | $29.41 | 03/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941500105 | CMS |
| EMD Serono, Inc. | $1,526.03 | 03/12/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941500249 | CMS |
| EMD Serono, Inc. | $22.28 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941499497 | CMS |
| Alexion Pharmaceuticals, Inc. | $14.23 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914791733 | CMS |
| Biogen, Inc. | $1.32 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923407423 | CMS |
| Biogen, Inc. | $26.38 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923420811 | CMS |
| SK Life Science, Inc. | $16.31 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940720589 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,030.00 | 03/08/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932728119 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.15 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923601105 | CMS |
| Novartis Pharmaceuticals Corporation | $5.00 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893707015 | CMS |
| Novartis Pharmaceuticals Corporation | $6.55 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893707019 | CMS |
| Avion Pharmaceuticals | $19.18 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 926521611 | CMS |
| EMD Serono, Inc. | $19.29 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941495469 | CMS |
| ABBVIE INC. | $23.38 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891051665 | CMS |
| E.R. Squibb & Sons, L.L.C. | $112.99 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932728121 | CMS |
| Horizon Therapeutics plc | $14.00 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937625973 | CMS |
| Janssen Pharmaceuticals, Inc | $18.05 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886797909 | CMS |
| Mallinckrodt Hospital Products Inc. | $124.59 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937499155 | CMS |
| SK Life Science, Inc. | $16.32 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940720585 | CMS |
| Horizon Therapeutics plc | $24.97 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937625971 | CMS |
| Biogen, Inc. | $23.52 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923462361 | CMS |
| EISAI INC. | $12.46 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908056809 | CMS |
| Celgene Corporation | $14.63 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932728127 | CMS |
| EMD Serono, Inc. | $275.00 | 02/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941491709 | CMS |
| Genentech USA, Inc. | $23.93 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950798945 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $18,424.54 | 11 |
| PY2025 | Principal investigator | $537,713.02 | 42 |
| PY2024 | Recipient | $15,557.38 | 26 |
| PY2024 | Principal investigator | $508,495.62 | 27 |
| PY2023 | Recipient | $300.00 | 1 |
| PY2023 | Principal investigator | $578,831.07 | 51 |
| PY2022 | Recipient | $4,038.00 | 2 |
| PY2022 | Principal investigator | $1,076,545.57 | 64 |
| PY2021 | Principal investigator | $1,180,096.38 | 38 |
| PY2020 | Recipient | $2,220.93 | 2 |
| PY2020 | Principal investigator | $1,209,008.22 | 37 |
| PY2019 | Recipient | $2,967.30 | 1 |
| PY2019 | Principal investigator | $1,281,674.25 | 94 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $46,180.85 | 12/15/2025 | Non-covered Recipient Entity The University Of Cincinnati Foundation | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226120737 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,002.90 | 12/10/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198925 |
| Principal investigator 1 | TG Therapeutics, Inc. | $21,896.34 | 12/09/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198933 |
| Recipient | F. Hoffmann-La Roche AG | $763.30 | 11/28/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537336 |
| Principal investigator 1 | TG Therapeutics, Inc. | $45,000.00 | 11/24/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198935 |
| Principal investigator 1 | GENZYME CORPORATION | $11,240.10 | 11/17/2025 | Non-covered Recipient Entity The University Of Cincinnati Foundation | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226120726 |
| Principal investigator 1 | Genentech, Inc. | $9,438.00 | 11/03/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677797 |
| Principal investigator 1 | TG Therapeutics, Inc. | $26,263.06 | 11/01/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198931 |
| Principal investigator 1 | GENZYME CORPORATION | $33,320.00 | 10/27/2025 | Non-covered Recipient Entity The University Of Cincinnati Foundation | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226120722 |
| Principal investigator 1 | Genentech, Inc. | $14,517.00 | 10/17/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677791 |
| Principal investigator 1 | Genentech, Inc. | $6,570.00 | 10/08/2025 | Non-covered Recipient Entity University of Cincinnati | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211677719 |
| Recipient | F. Hoffmann-La Roche AG | $424.06 | 10/03/2025 | Covered Recipient Physician | Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial | No dispute reported | 06/30/2026 | 1211537313 |
| Recipient | F. Hoffmann-La Roche AG | $1,090.56 | 10/02/2025 | Covered Recipient Physician | Efficacy Tolerability of Ocrelizumab in African Americans Hispanic Americans vs Caucasians | No dispute reported | 06/30/2026 | 1211537331 |
| Principal investigator 1 | Genentech, Inc. | $6,950.00 | 10/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | OCARINA I | No dispute reported | 06/30/2026 | 1211677759 |
| Principal investigator 1 | Genentech, Inc. | $5,809.47 | 10/02/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677793 |
| Principal investigator 1 | TG Therapeutics, Inc. | $35,927.72 | 09/30/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198897 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,601.16 | 09/25/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198917 |
| Recipient | F. Hoffmann-La Roche AG | $2,174.11 | 09/24/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537340 |
| Principal investigator 1 | Genentech, Inc. | $7,258.50 | 09/19/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677789 |
| Principal investigator 1 | TG Therapeutics, Inc. | $32,424.59 | 08/31/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198895 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,868.02 | 08/25/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198915 |
| Principal investigator 1 | Genentech, Inc. | $6,597.00 | 08/20/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | OCARINA I | No dispute reported | 06/30/2026 | 1211677761 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,868.02 | 08/20/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198913 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,868.02 | 08/18/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198911 |
| Principal investigator 1 | EMD Serono, Inc. | $26,062.00 | 08/14/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI | A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) | No dispute reported | 06/30/2026 | 1240118563 |
| Principal investigator 1 | TG Therapeutics, Inc. | $800.58 | 08/14/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198909 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,067.44 | 08/05/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198907 |
| Principal investigator 1 | TG Therapeutics, Inc. | $13,755.84 | 07/31/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198893 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,736.04 | 07/21/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198905 |
| Principal investigator 1 | GENZYME CORPORATION | $38,450.00 | 07/14/2025 | Non-covered Recipient Entity The University Of Cincinnati Foundation | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226120673 |
| Principal investigator 1 | TG Therapeutics, Inc. | $23,368.02 | 06/01/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198867 |
| Principal investigator 1 | Genentech, Inc. | $10,995.00 | 05/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | OCARINA I | No dispute reported | 06/30/2026 | 1211677749 |
| Recipient | F. Hoffmann-La Roche AG | $6,011.55 | 05/13/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537306 |
| Principal investigator 1 | GENZYME CORPORATION | $6,530.00 | 05/05/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians Company Llc | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226081971 |
| Principal investigator 1 | Genentech, Inc. | $181.20 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677785 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,404.64 | 04/28/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198889 |
| Recipient | F. Hoffmann-La Roche AG | $6,022.93 | 04/17/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537303 |
| Principal investigator 1 | Genentech, Inc. | $7,126.00 | 04/16/2025 | Non-covered Recipient Entity University of Cincinnati | First in human study RO7121932 | No dispute reported | 06/30/2026 | 1211677735 |
| Recipient | F. Hoffmann-La Roche AG | $244.13 | 04/08/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537328 |
| Recipient | F. Hoffmann-La Roche AG | $436.50 | 04/05/2025 | Covered Recipient Physician | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211537309 |
| Recipient | F. Hoffmann-La Roche AG | $436.36 | 03/31/2025 | Covered Recipient Physician | OCARINA I | No dispute reported | 06/30/2026 | 1211537318 |
| Recipient | F. Hoffmann-La Roche AG | $423.66 | 03/31/2025 | Covered Recipient Physician | OCARINA I | No dispute reported | 06/30/2026 | 1211537321 |
| Recipient | F. Hoffmann-La Roche AG | $397.38 | 03/31/2025 | Covered Recipient Physician | OCARINA I | No dispute reported | 06/30/2026 | 1211537325 |
| Principal investigator 1 | TG Therapeutics, Inc. | $17,571.67 | 03/31/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198865 |
| Principal investigator 1 | Genentech, Inc. | $12,664.00 | 03/20/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC | OCARINA I | No dispute reported | 06/30/2026 | 1211677757 |
| Principal investigator 1 | GENZYME CORPORATION | $5,498.00 | 03/17/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians Company Llc | Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226081966 |
| Principal investigator 1 | Genentech, Inc. | $9,288.00 | 03/05/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS INC LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211677783 |
| Principal investigator 1 | TG Therapeutics, Inc. | $13,758.48 | 02/28/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198863 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,202.32 | 02/26/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198885 |
| Principal investigator 1 | Genentech, Inc. | $8,096.00 | 02/04/2025 | Non-covered Recipient Entity University of Cincinnati | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211677717 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,202.32 | 01/30/2025 | Non-covered Recipient Entity University of Cincinnati | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198883 |
| Principal investigator 1 | Genentech, Inc. | $4,897.00 | 01/14/2025 | Non-covered Recipient Entity University of Cincinnati | Ocrelizumab SC Phase III | No dispute reported | 06/30/2026 | 1211677715 |
| Principal investigator 1 | Eli Lilly and Company | $457.72 | 01/09/2025 | Non-covered Recipient Entity UNIVERSITY OF CINCINNATI PHYSICIANS | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187893556 |